Dopamine D₂ Antagonists Impact Nicotine Reward Processing in Schizophrenia₂-antagonists-impact-nicotine-reward-processing-in-schizophrenia/

Patients with schizophrenia who are prescribed potent dopamine D₂ receptor antagonists often increase smoking and experience difficulty quitting. Possibly, this is due to a mechanism of these medications to reduce the reward-enhancing effect of nicotine, according to a study published in Schizophrenia Bulletin .

Abilify has a very addictive quality to it, so I’m not too surprised

1 Like